0000950170-24-006661.txt : 20240123 0000950170-24-006661.hdr.sgml : 20240123 20240123172947 ACCESSION NUMBER: 0000950170-24-006661 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240122 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION BIOSCIENCES INC CENTRAL INDEX KEY: 0001357874 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38841 FILM NUMBER: 24553625 BUSINESS ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 BUSINESS PHONE: 919-314-5512 MAIL ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 8-K 1 dtil-20240122.htm 8-K 8-K
false0001357874Nasdaq00013578742024-01-222024-01-22

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2024

 

 

Precision BioSciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38841

20-4206017

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

302 East Pettigrew St.

Suite A-100

 

Durham, North Carolina

 

27701

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 919 314-5512

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.000005 per share

 

DTIL

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 22, 2024, Precision BioSciences, Inc. (the “Company”) entered into new employment agreements with each of: Michael Amoroso, the Company’s President and Chief Executive Officer; Alex Kelly, the Company’s Chief Financial Officer; Dario Scimeca, the Company’s General Counsel and Secretary; and Jeff Smith, the Company’s Chief Research Officer. The employment agreements are similar to their prior employment agreements, except that they will reflect current annual base salary and target bonus amounts and increased severance and benefit amounts payable in connection with a termination without “cause” or resignation for “good reason” (each, as defined in the respective employment agreements). In connection with either such a termination, subject to the timely execution of a release of claims and continued compliance with obligations under proprietary information agreements, the foregoing executive officers are entitled to receive severance composed of: 12 months of the executive’s then-base salary (18 months for Mr. Amoroso); one times the executive’s bonus at the target payout level (one and a half times the target bonus for Mr. Amoroso); 12 months of COBRA employee premiums (18 months for Mr. Amoroso); accelerated vesting of the executive’s then-unvested time-based equity grants that would have vested within the 13 months following the date of termination (25 months for Mr. Amoroso); and a one-year post-termination exercise period for the executive’s then-outstanding options (two years for Mr. Amoroso if the termination occurs within two years of the date of his employment agreement). If, however, such a termination occurs within the three-month period prior to, or 12-month period following, a “change in control” (as defined in the employment agreement and, with respect to Mr. Amoroso, within two years of the date of his employment agreement), in lieu of the foregoing severance, each such executive officer is entitled to receive: 18 months of the executive’s then-base salary (24 months for Mr. Amoroso); the executive’s bonus at one and a half times the target payout level (two times target bonus for Mr. Amoroso); 18 months of COBRA employee premiums; accelerated vesting of then-unvested time-based equity grants; and a one year post-termination exercise period for options that are assumed in the change in control (two years for Mr. Amoroso).

The foregoing descriptions of the employment agreements are qualified in their entirety by reference to the full text of such employment agreements, which are filed as Exhibits 10.1, 10.2, 10.3 and 10.4 to this Current Report on Form 8-K and incorporated by reference herein.

 


 

Item 9.01 Financial Statements and Exhibits.

 

 

(d)

Exhibits

Exhibit
No.

Description

10.1

Executive Employment Agreement, dated January 22, 2024, by and between Michael Amoroso and Precision BioSciences, Inc.

 

 

 

10.2

Executive Employment Agreement, dated January 22, 2024, by and between Alex Kelly and Precision BioSciences, Inc.

 

 

 

10.3

 

Executive Employment Agreement, dated January 22, 2024, by and between Dario Scimeca and Precision BioSciences, Inc.

 

 

 

10.4

 

Executive Employment Agreement, dated January 22, 2024, by and between Jeff Smith and Precision BioSciences, Inc.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PRECISION BIOSCIENCES, INC.

 

 

 

 

Date:

January 23, 2024

By:

/s/ Dario Scimeca

 

 

 

Dario Scimeca

General Counsel

 


EX-10.1 2 dtil-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

img72316305_0.jpg 

 

Executive EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Michael Amoroso (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

BACKGROUND

The Company wishes to continue to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

1.
EMPLOYMENT. As of the Effective Date, the Company hereby continues to employ Executive as the President and Chief Executive Officer of the Company upon the terms and conditions of this Agreement and Executive accepts continued employment with the Company upon the terms and conditions of this Agreement. This Agreement supersedes and replaces Executive’s Employment Agreement with the Company dated September 18, 2021 (the “Prior Employment Agreement”).
2.
NATURE OF EMPLOYMENT/DUTIES. Executive shall serve as the President and Chief Executive Officer of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive’s title and position.
2.1
Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.
2.2
Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive’s duties and advance the Company’s interests. During Executive’s employment, Executive may, with the Board of Director’s (the “Board”) consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive’s obligations hereunder.
3.
COMPENSATION.
3.1
Base Salary. During the Term, Executive’s annual base salary for all services rendered shall be Six Hundred Thousand Thirty Five Thousand and 00/100 Dollars

 

|US-DOCS\146536256.4||


 

($635,000.00) (less applicable taxes and withholdings) payable in accordance with the Company’s payroll practices as they may exist from time to time (“Base Salary”). Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company’s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.
3.2
Business Expenses. Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time. All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.
3.3
Bonus. During the Term, Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans. Executive’s annual incentive compensation under such bonus plan (the “Annual Bonus”) shall be targeted at sixty percent (60%) of Executive’s Base Salary (such target, as may be increased by the Board from time to time, the “Target Annual Bonus”). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive’s continued employment with the Company through the date of payment.
3.4
Equity Compensation. Executive has received equity compensation from the Company and will continue to be eligible for awards of equity compensation in the Board’s (or its delegates) discretion.
3.5
Benefits. During the Term, Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive’s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion, as they may exist from time to time. The Company shall pay annual dues and expenses for Executive’s membership and participation in such professional organizations as may be approved by the Board.
3.6
Indemnification; D&O Insurance. Both during and after the Term, the Company hereby agrees to indemnify Executive and hold Executive harmless to the maximum extent permitted by the Company’s organizational documents as in effect from time to time against and in respect of any and all actions, suits, proceedings, investigations, claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages resulting from Executive’s good faith performance of Executive’s duties and obligations with the Company hereunder; provided, that, while Executive may have rights to indemnification with respect to certain matters related to a restatement or other event, Executive shall have no rights to indemnification with respect to any amounts that are subject to recoupment from Executive or forfeiture by Executive pursuant to a Clawback (as defined below). The Company shall cover the

2

 

|US-DOCS\146536256.4||


 

Executive under directors’ and officers’ liability insurance to the same extent as the Company covers its other active officers and directors. The foregoing obligations shall survive the termination of Executive’s employment with the Company.
4.
TERM OF EMPLOYMENT AND TERMINATION. The Company and Executive acknowledge that Executive's employment is and shall continue to be at-will, as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive’s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4. The date on which Executive’s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the “Separation Date.” Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.
4.1
Without Cause, Upon Notice. Either the Company or Executive may terminate Executive’s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.
4.2
For Cause. The Company may terminate Executive’s employment and this Agreement immediately without notice at any time for “Cause,” which shall mean the following:
4.2.1
Executive's material failure to perform Executive’s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board (other than any such failure resulting from incapacity due to physical or mental illness);
4.2.2
Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;
4.2.3
Executive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;
4.2.4
Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent);
4.2.5
Executive’s failure to cooperate with the Company in any investigation or formal proceeding;
4.2.6
Executive's material breach of any material obligation under this Agreement, the Restrictive Covenant Agreement (as defined in Section 6), or any other written agreement between the Executive and the Company; or
4.2.7
any material failure by Executive to comply with the Company's written policies or rules, as they may be in effect from time to time.

3

 

|US-DOCS\146536256.4||


 

Provided, however, that prior to termination based on Sections 4.2.1, 4.2.5, 4.2.6 or 4.2.7, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.

4.3
By Death or Disability. Executive’s employment and this Agreement shall terminate upon Executive’s Disability or death. For purposes of this Agreement, “Disability” shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.
4.4
For Good Reason. Executive may terminate Executive’s employment for “Good Reason,” which shall mean the occurrence of any of the following, in each case without the Executive's written consent:
4.4.1
a material reduction in Executive's Base Salary by an amount equivalent to ten percent (10%) or greater, other than a general reduction in Base Salary that affects all similarly situated executives;
4.4.2
material, adverse change in Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law),
4.4.3
an involuntary relocation of the Executive's principal place of employment by more than thirty five (35) miles; or
4.4.4
the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law.

Executive cannot terminate Executive’s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within sixty (60) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to

4

 

|US-DOCS\146536256.4||


 

cure such circumstances. If the Executive does not terminate Executive’s employment for Good Reason within ninety (90) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive’s right to terminate for Good Reason with respect to such grounds.

 

5.
COMPENSATION AND BENEFITS UPON TERMINATION. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "Accrued Obligations"). Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.
5.1
By the Company for Cause or because of Executive’s Death or Disability, or by Executive Without Cause, Upon Notice. If Executive’s employment and this Agreement are terminated by the Company for Cause or because of Executive’s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company’s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.
5.2
By the Company Without Cause or by Executive for Good Reason. If the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following; provided, however, if the Separation Date occurs for the reasons set forth in this Section 5.2 within two (2) years following the Effective Date, Executive shall be entitled to the payments and benefits set forth in Section 5.3 in lieu of any payments or benefits under Section 5.2, subject to the conditions set forth therein:
5.2.1
pay Executive an amount equal to eighteen (18) months of Executive’s then current monthly Annual Base Salary (less applicable taxes and withholdings) (the “Severance Amount”), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive’s separation from service and over the eighteen month period (the “Severance Period”) commencing on the first such payroll date on or following the Release Effective Date (as defined in Section 5.5 below), but not later

5

 

|US-DOCS\146536256.4||


 

than seventy (70) days following the Separation Date; provided however that if the 70th day following the Separation Date occurs in the year following the year in which the Separation Date occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided further that the first such payment shall be a lump sum payment in an amount equal to any portion of the Severance Amount that exceeds two times the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Date of Termination occurs and the remainder of the Severance Amount shall be paid over the remainder of the eighteen (18) month period;
5.2.2
an amount equal to one and a half (1.5) times the Target Annual Bonus, payable in lump sum no later than seventy (70) days following the Separation Date;
5.2.3
If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the end of the Severance Period; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.3 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.2.4
Executive’s unvested time-based equity grants shall vest as of the Separation Date with respect to that portion of such unvested time-based equity grants that would have vested within the twenty-five (25) month period immediately following the Separation Date based solely on the passage of time had Executive remained employed by the Company through such period, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.2.5
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date (two (2) years if the Separation Date occurs within two (2) years following the Effective Date), (b) the maximum term of the applicable stock option, and (c) unless such options are assumed or substituted in the Change in Control, the date of a Change in Control.
5.3
During the Change in Control Termination Period, by the Company Without Cause or by Executive for Good Reason. If during the Change in Control Termination

6

 

|US-DOCS\146536256.4||


 

Period, as defined herein, either the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any payments or benefits under Section 5.2, and subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement, the Company shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.3.1
The Company shall pay Executive an amount equal to twenty-four (24) months of Executive’s then current monthly base salary (less applicable taxes and withholdings) (the “CIC Severance Period”) plus two (2) times Executive’s target bonus for the year during which the Separation Date occurs, payable in lump sum no later than seventy (70) days following the Separation Date; provided, that, if the Separation Date occurs within three (3) months prior to a Change in Control, any amounts payable under this Section 5.3.1 (excluding any amount payable under either Section 5.2.1 or 5.2.2 prior to the date thirty (30) days following the date of the Change in Control) shall be paid no later than the date falling on the later of (a) seventy (70) days following the Separation Date, and (b) thirty (30) days following the date of the Change in Control;
5.3.2
If Executive timely and properly elects health continuation coverage under COBRA, during the eighteen (18) month period following the Separation Date, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the eighteen-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.3.3
All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.3.4
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date two (2) years following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless the

7

 

|US-DOCS\146536256.4||


 

applicable options are assumed or substituted in the Change in Control, the date of a Change in Control.

 

5.4
Definition of Change in Control and Change in Control Termination Period.
5.4.1
Change in Control” means and includes each of the following:
(a)
A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, “Subsidiary” means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or
(b)
During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)
The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:
(i)
which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or

8

 

|US-DOCS\146536256.4||


 

substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
(ii)
after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction, and
(iii)
after which at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity immediately following the date of such transaction were Board members immediately prior to the date of such transaction.
5.4.2
Change in Control Termination Period” shall mean the period beginning three (3) months prior to and ending twelve (12) months following the occurrence of a Change in Control.
5.4.3
Notwithstanding the foregoing, if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”), to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).
5.4.4
The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.
5.5
Required Release. Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide the payments, acceleration, exercise extension and reimbursements under Sections 5.2 and 5.3 is conditioned upon Executive’s execution of a standard form of an enforceable release of claims (the “Release”) and Executive’s compliance with the Restrictive Covenant Agreement. If Executive chooses not to execute such the Release or fails to comply with the Restrictive Covenant Agreement, then the Company’s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time. The Release shall be provided to Executive within ten (10) days of Executive’s separation from service and Executive must execute it within the time period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). Such Release shall not be effective until any applicable revocation period has expired (the “Release Effective Date”).

9

 

|US-DOCS\146536256.4||


 

5.6
Benefits in Lieu of Other Severance. Executive is not entitled to receive any compensation or benefits upon Executive’s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.
6.
Restrictive Covenants. As a condition of continued employment, Executive will continue to be subject to the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, which the Executive previously executed (the “Restrictive Covenant Agreement”). Executive agrees to continue to abide by the terms of the Restrictive Covenant Agreement, or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement, or any subsequent similar agreement, will survive the termination of Executive's employment and/or the termination of this Agreement.
7.
Company Property. Upon the termination of Executive’s employment or upon Company’s earlier request, Executive shall: (i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive’s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive’s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive’s work and transferring that work to other individuals designated by the Company.
8.
EMPLOYEE REPRESENTATION. Executive represents and warrants that Executive’s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.
9.
Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.
10.
ENTIRE AGREEMENT. Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written,

10

 

|US-DOCS\146536256.4||


 

with respect to Executive’s employment with the Company, including the Prior Employment Agreement; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter. Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid. No change or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.
11.
SEVERABILITY. If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.
12.
Assignment and Successors. The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law.
13.
GOVERNING LAW. This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (“Applicable Federal Law”). Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.
14.
COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.
15.
Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:
15.1
If to the Company, to the General Counsel of the Company at the Company's headquarters,

11

 

|US-DOCS\146536256.4||


 

15.2
If to Executive, to the last address that the Company has in its personnel records for Executive, or
15.3
At any other address as any Party shall have specified by notice in writing to the other Party.
16.
SECTION 409A OF THE INTERNAL REVENUE CODE. The parties intend that the provisions of this Agreement comply with or are exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.
16.1
Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service.
16.2
Separate Payments. Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.
16.3
Delayed Distribution to Specified Employee. If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company’s sole discretion, that Executive is a Specified Employee of the Company on the date Executive’s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the Separation Date (the “409A Delay Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Specified Employee” shall mean an employee who, on an Identification Date (“Identification Date” shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without

12

 

|US-DOCS\146536256.4||


 

regard to paragraph (5) thereof. If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.
16.4
Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following: (a) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (c) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.
17.
Parachute Payments. Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "Total Payments"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).
17.1
Order of Reduction. The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code ("Section 409A"), (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.
17.2
Determinations. All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "Independent Advisors"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i)

13

 

|US-DOCS\146536256.4||


 

does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.
17.3
Additional Reductions. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.
18.
WITHHOLDING. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold.
19.
CLAWBACK. If any law, rule, or regulation applicable to the Company or its Subsidiaries (including any rule or requirement of any nationally recognized stock exchange on which the stock of the Company or its Subsidiaries is listed), or any policy of the Company or its Subsidiaries reasonably designed to comply therewith, requires the forfeiture or recoupment of any amount paid or payable to the Executive hereunder (or under any other agreement between the Executive and the Company or its Subsidiaries or under any plan in which the Executive participates, or otherwise payable to the Executive as compensation for services), the Executive hereby consents to such forfeiture or recoupment, in each case in the time and manner determined by the Company in its reasonable good faith discretion (collectively, the “Clawback”).

 

[The remainder of this page is intentionally left blank.]

 

14

 

|US-DOCS\146536256.4||


 

[Signature Page for Employment Agreement]

 

 

IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.

 

 

MICHAEL AMOROSO

 

 

/s/ MICHAEL AMOROSO

 

 

 

Precision Biosciences, Inc.

 

/s/ DARIO SCIMECA

 

By: Dario Scimeca

 

Title: General Counsel and Corporate Secretary

 

15

 

|US-DOCS\146536256.4||


EX-10.2 3 dtil-ex10_2.htm EX-10.2 EX-10.2

EXHIBIT 10.2

img73239826_0.jpg 

 

Executive EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and John Alexander Kelly (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

BACKGROUND

The Company wishes to continue to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

1.
EMPLOYMENT. As of the Effective Date, the Company hereby continues to employ Executive as Chief Financial Officer of the Company upon the terms and conditions of this Agreement and Executive accepts continued employment with the Company upon the terms and conditions of this Agreement. This Agreement supersedes and replaces Executive’s Employment Agreement with the Company dated May 27, 2021, as amended (the “Prior Employment Agreement”).
2.
NATURE OF EMPLOYMENT/DUTIES. Executive shall serve as Chief Financial Officer of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive’s title and position.
2.1
Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.
2.2
Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive’s duties and advance the Company’s interests. During Executive’s employment, Executive may, with the Board’s consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive’s obligations hereunder.

 

 


 

3.
COMPENSATION.
3.1
Base Salary. During the Term, Executive’s annual base salary for all services rendered shall be Four Hundred Sixty-One Thousand and 00/100 Dollars ($461,000.00) (less applicable taxes and withholdings) payable in accordance with the Company’s payroll practices as they may exist from time to time (“Base Salary”). Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company’s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.
3.2
Business Expenses. Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time. All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.
3.3
Bonus. During the Term, Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans. Executive’s annual incentive compensation under such bonus plan (the “Annual Bonus”) shall be targeted at forty percent (40%) of Executive’s Base Salary (such target, as may be increased by the Board from time to time, the “Target Annual Bonus”). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive’s continued employment with the Company through the date of payment.
3.4
Benefits. During the Term, Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive’s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion, as they may exist from time to time. The Company shall pay annual dues and expenses for Executive’s membership and participation in such professional organizations as may be approved by the Board.
3.5
Indemnification; D&O Insurance. Both during and after the Term, the Company hereby agrees to indemnify Executive and hold Executive harmless to the maximum extent permitted by the Company’s organizational documents as in effect from time to time against and in respect of any and all actions, suits, proceedings, investigations, claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages resulting from Executive’s good faith performance of Executive’s duties and obligations with the Company hereunder; provided, that, Executive shall have no rights to indemnification with respect to any amounts subject to Clawback (as defined below). The Company shall cover the Executive under directors’ and officers’ liability insurance to the same extent as the Company covers its other active

2

 


 

officers and directors. The foregoing obligations shall survive the termination of Executive’s employment with the Company.
4.
TERM OF EMPLOYMENT AND TERMINATION. The Company and Executive acknowledge that Executive's employment is and shall continue to be at-will, as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive’s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4. The date on which Executive’s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the “Separation Date.” Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.
4.1
Without Cause, Upon Notice. Either the Company or Executive may terminate Executive’s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.
4.2
For Cause. The Company may terminate Executive’s employment and this Agreement immediately without notice at any time for “Cause,” which shall mean the following:
4.2.1
Executive's material failure to perform Executive’s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors (other than any such failure resulting from incapacity due to physical or mental illness);
4.2.2
Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;
4.2.3
Executive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;
4.2.4
Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;
4.2.5
Executive’s failure to cooperate with the Company in any investigation or formal proceeding;
4.2.6
Executive's material breach of any material obligation under this Agreement, the Restrictive Covenant Agreement (as defined in Section 6), or any other written agreement between the Executive and the Company; or
4.2.7
any material failure by Executive to comply with the Company's written policies or rules, as they may be in effect from time to time.

3

 


 

Provided, however, that prior to termination based on Sections 4.2.1, 4.2.5, 4.2.6 or 4.2.7, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.

4.3
By Death or Disability. Executive’s employment and this Agreement shall terminate upon Executive’s Disability or death. For purposes of this Agreement, “Disability” shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.
4.4
For Good Reason. Executive may terminate Executive’s employment for “Good Reason,” which shall mean the occurrence of any of the following, in each case without the Executive's written consent:
4.4.1
a material reduction in Executive's Base Salary by an amount equivalent to ten percent (10%) or greater, other than a general reduction in Base Salary that affects all similarly situated executives;
4.4.2
material, adverse change in Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law),
4.4.3
an involuntary relocation of the Executive's principal place of employment by more than thirty five (35) miles; or
4.4.4
the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law.

Executive cannot terminate Executive’s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within sixty (60) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to

4

 


 

cure such circumstances. If the Executive does not terminate Executive’s employment for Good Reason within ninety (90) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive’s right to terminate for Good Reason with respect to such grounds.

 

5.
COMPENSATION AND BENEFITS UPON TERMINATION. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "Accrued Obligations"). Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.
5.1
By the Company for Cause or because of Executive’s Death or Disability, or by Executive Without Cause, Upon Notice. If Executive’s employment and this Agreement are terminated by the Company for Cause or because of Executive’s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company’s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.
5.2
By the Company Without Cause or by Executive for Good Reason. If the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.2.1
pay Executive an amount equal to twelve(12) months of Executive’s then current monthly Annual Base Salary (less applicable taxes and withholdings) (the “Severance Amount”), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive’s separation from service and over the twelve month period (the “Severance Period”) commencing on the first such payroll date on or following the Release Effective Date (as defined in Section 5.5 below), but not later than seventy (70) days following the Separation Date; provided however that if the 70th day following the Separation Date occurs in the year following the year in which the Separation Date occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided

5

 


 

further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments missed between the Separation Date and the Release Effective Date;
5.2.2
an amount equal to one (1.0) times the Target Annual Bonus, payable in lump sum no later than seventy (70) days following the Separation Date;
5.2.3
If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the end of the Severance Period; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.3 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.2.4
Executive’s unvested time-based equity grants shall vest as of the Separation Date with respect to that portion of such unvested time-based equity grants that would have vested within the thirteen (13) month period immediately following the Separation Date based solely on the passage of time had Executive remained employed by the Company through such period, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.2.5
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless such options are assumed or substituted in the Change in Control, the date of a Change in Control.
5.3
During the Change in Control Termination Period, by the Company Without Cause or by Executive for Good Reason. If during the Change in Control Termination Period, as defined herein, either the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any payments or benefits under Section 5.2, and subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement, the Company

6

 


 

shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.3.1
The Company shall pay Executive an amount equal to eighteen (18) months of Executive’s then current monthly base salary (less applicable taxes and withholdings) (the “CIC Severance Period”) plus one and a half (1.5) times Executive’s target bonus for the year during which the Separation Date occurs, payable in lump sum no later than seventy (70) days following the Separation Date; provided, that, if the Separation Date occurs within three (3) months prior to a Change in Control, any amounts payable under this Section 5.3.1 (excluding any amount payable under either Section 5.2.1 or 5.2.2 prior to the date thirty (30) days following the date of the Change in Control) shall be paid no later than the date falling on the later of (a) seventy (70) days following the Separation Date, and (b) thirty (30) days following the date of the Change in Control;
5.3.2
If Executive timely and properly elects health continuation coverage under COBRA, during the eighteen (18) month period following the Separation Date, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the eighteen-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.3.3
All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.3.4
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless the applicable options are assumed or substituted in the Change in Control, the date of a Change in Control.

 

5.4
Definition of Change in Control and Change in Control Termination Period.

7

 


 

5.4.1
Change in Control” means and includes each of the following:
(a)
A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, “Subsidiary” means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or
(b)
During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board of Directors (the “Board”) together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)
The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:
(i)
which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
(ii)
after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity;

8

 


 

provided, however, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction, and
(iii)
after which at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity immediately following the date of such transaction were Board members immediately prior to the date of such transaction.
5.4.2
Change in Control Termination Period” shall mean the period beginning three (3) months prior to and ending twelve (12) months following the occurrence of a Change in Control.
5.4.3
Notwithstanding the foregoing, if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”), to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).
5.4.4
The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.
5.5
Required Release. Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide the payments, acceleration, exercise extension and reimbursements under Sections 5.2 and 5.3 is conditioned upon Executive’s execution of a standard form of an enforceable release of claims (the “Release”) and Executive’s compliance with the Restrictive Covenant Agreement. If Executive chooses not to execute such the Release or fails to comply with the Restrictive Covenant Agreement, then the Company’s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time. The Release shall be provided to Executive within ten (10) days of Executive’s separation from service and Executive must execute it within the time period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). Such Release shall not be effective until any applicable revocation period has expired (the “Release Effective Date”).
5.6
Benefits in Lieu of Other Severance. Executive is not entitled to receive any compensation or benefits upon Executive’s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.

9

 


 

6.
Restrictive Covenants. As a condition of continued employment, Executive will continue to be subject to the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, which the Executive previously executed (the “Restrictive Covenant Agreement”). Executive agrees to continue to abide by the terms of the Restrictive Covenant Agreement, or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement, or any subsequent similar agreement, will survive the termination of Executive's employment and/or the termination of this Agreement.
7.
Company Property. Upon the termination of Executive’s employment or upon Company’s earlier request, Executive shall: (i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive’s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive’s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive’s work and transferring that work to other individuals designated by the Company.
8.
EMPLOYEE REPRESENTATION. Executive represents and warrants that Executive’s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.
9.
Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.
10.
ENTIRE AGREEMENT. Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive’s employment with the Company, including the Prior Employment Agreement; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter. Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid. No change

10

 


 

or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.
11.
SEVERABILITY. If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.
12.
Assignment and Successors. The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law.
13.
GOVERNING LAW. This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (“Applicable Federal Law”). Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.
14.
COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.
15.
Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:
15.1
If to the Company, to the General Counsel of the Company at the Company's headquarters,
15.2
If to Executive, to the last address that the Company has in its personnel records for Executive, or
15.3
At any other address as any Party shall have specified by notice in writing to the other Party.
16.
SECTION 409A OF THE INTERNAL REVENUE CODE. The parties intend that the provisions of this Agreement comply with or are exempt from Section 409A of the Internal

11

 


 

Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.
16.1
Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service.
16.2
Separate Payments. Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.
16.3
Delayed Distribution to Specified Employee. If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company’s sole discretion, that Executive is a Specified Employee of the Company on the date Executive’s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the Separation Date (the “409A Delay Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Specified Employee” shall mean an employee who, on an Identification Date (“Identification Date” shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof. If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.
16.4
Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following: (a) the amount of expenses eligible for reimbursement, or in-kind benefits

12

 


 

provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (c) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.
17.
Parachute Payments. Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "Total Payments"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).
17.1
Order of Reduction. The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code ("Section 409A"), (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.
17.2
Determinations. All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "Independent Advisors"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.

13

 


 

17.3
Additional Reductions. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.
18.
WITHHOLDING. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold.
19.
CLAWBACK. If any law, rule, or regulation applicable to the Company or its Subsidiaries (including any rule or requirement of any nationally recognized stock exchange on which the stock of the Company or its Subsidiaries is listed), or any policy of the Company or its Subsidiaries reasonably designed to comply therewith, requires the forfeiture or recoupment of any amount paid or payable to the Executive hereunder (or under any other agreement between the Executive and the Company or its Subsidiaries or under any plan in which the Executive participates, or otherwise payable to the Executive as compensation for services), the Executive hereby consents to such forfeiture or recoupment, in each case in the time and manner determined by the Company in its reasonable good faith discretion (collectively, the “Clawback”).

 

[The remainder of this page is intentionally left blank.]

 

14

 


 

[Signature Page for Employment Agreement]

 

 

IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.

 

 

john alexander kelly

 

 

 

/s/ JOHN ALEXANDER KELLY

 

 

 

Precision Biosciences, Inc.

 

/s/ MICHAEL AMOROSO

 

By: Michael Amoroso

 

Title: President and Chief Executive Officer

15

 


EX-10.3 4 dtil-ex10_3.htm EX-10.3 EX-10.3

EXHIBIT 10.3

img74163347_0.jpg 

 

Executive EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Dario Scimeca (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

BACKGROUND

The Company wishes to continue to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

1.
EMPLOYMENT. As of the Effective Date, the Company hereby continues to employ Executive as General Counsel and Corporate Secretary of the Company upon the terms and conditions of this Agreement and Executive accepts continued employment with the Company upon the terms and conditions of this Agreement. This Agreement supersedes and replaces Executive’s Employment Agreement with the Company dated March 15, 2019, as amended (the “Prior Employment Agreement”).
2.
NATURE OF EMPLOYMENT/DUTIES. Executive shall serve as General Counsel and Corporate Secretary of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive’s title and position.
2.1
Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.
2.2
Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive’s duties and advance the Company’s interests. During Executive’s employment, Executive may, with the Board’s consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive’s obligations hereunder.

 

 

|US-DOCS\146536256.4||


 

3.
COMPENSATION.
3.1
Base Salary. During the Term, Executive’s annual base salary for all services rendered shall be Four Hundred Twenty-Eight Thousand and 00/100 Dollars ($428,000) (less applicable taxes and withholdings) payable in accordance with the Company’s payroll practices as they may exist from time to time (“Base Salary”). Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company’s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.
3.2
Business Expenses. Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time. All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.
3.3
Bonus. During the Term, Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans. Executive’s annual incentive compensation under such bonus plan (the “Annual Bonus”) shall be targeted at forty percent (40%) of Executive’s Base Salary (such target, as may be increased by the Board from time to time, the “Target Annual Bonus”). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive’s continued employment with the Company through the date of payment.
3.4
Benefits. During the Term, Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive’s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion, as they may exist from time to time. The Company shall pay annual dues and expenses for Executive’s membership and participation in such professional organizations as may be approved by the Board.
3.5
Indemnification; D&O Insurance. Both during and after the Term, the Company hereby agrees to indemnify Executive and hold Executive harmless to the maximum extent permitted by the Company’s organizational documents as in effect from time to time against and in respect of any and all actions, suits, proceedings, investigations, claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages resulting from Executive’s good faith performance of Executive’s duties and obligations with the Company hereunder; provided, that, Executive shall have no rights to indemnification with respect to any amounts subject to Clawback (as defined below). The Company shall cover the Executive under directors’ and officers’ liability insurance to the same extent as the Company covers its other active

2

 


 

officers and directors. The foregoing obligations shall survive the termination of Executive’s employment with the Company.
4.
TERM OF EMPLOYMENT AND TERMINATION. The Company and Executive acknowledge that Executive's employment is and shall continue to be at-will, as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive’s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4. The date on which Executive’s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the “Separation Date.” Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.
4.1
Without Cause, Upon Notice. Either the Company or Executive may terminate Executive’s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.
4.2
For Cause. The Company may terminate Executive’s employment and this Agreement immediately without notice at any time for “Cause,” which shall mean the following:
4.2.1
Executive's material failure to perform Executive’s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors (other than any such failure resulting from incapacity due to physical or mental illness);
4.2.2
Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;
4.2.3
Executive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;
4.2.4
Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;
4.2.5
Executive’s failure to cooperate with the Company in any investigation or formal proceeding;
4.2.6
Executive's material breach of any material obligation under this Agreement, the Restrictive Covenant Agreement (as defined in Section 6), or any other written agreement between the Executive and the Company; or
4.2.7
any material failure by Executive to comply with the Company's written policies or rules, as they may be in effect from time to time.

3

 


 

Provided, however, that prior to termination based on Sections 4.2.1, 4.2.5, 4.2.6 or 4.2.7, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.

4.3
By Death or Disability. Executive’s employment and this Agreement shall terminate upon Executive’s Disability or death. For purposes of this Agreement, “Disability” shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.
4.4
For Good Reason. Executive may terminate Executive’s employment for “Good Reason,” which shall mean the occurrence of any of the following, in each case without the Executive's written consent:
4.4.1
a material reduction in Executive's Base Salary by an amount equivalent to ten percent (10%) or greater, other than a general reduction in Base Salary that affects all similarly situated executives;
4.4.2
material, adverse change in Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law),
4.4.3
an involuntary relocation of the Executive's principal place of employment by more than thirty five (35) miles; or
4.4.4
the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law.

Executive cannot terminate Executive’s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within sixty (60) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to

4

 


 

cure such circumstances. If the Executive does not terminate Executive’s employment for Good Reason within ninety (90) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive’s right to terminate for Good Reason with respect to such grounds.

 

5.
COMPENSATION AND BENEFITS UPON TERMINATION. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "Accrued Obligations"). Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.
5.1
By the Company for Cause or because of Executive’s Death or Disability, or by Executive Without Cause, Upon Notice. If Executive’s employment and this Agreement are terminated by the Company for Cause or because of Executive’s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company’s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.
5.2
By the Company Without Cause or by Executive for Good Reason. If the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.2.1
pay Executive an amount equal to twelve(12) months of Executive’s then current monthly Annual Base Salary (less applicable taxes and withholdings) (the “Severance Amount”), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive’s separation from service and over the twelve month period (the “Severance Period”) commencing on the first such payroll date on or following the Release Effective Date (as defined in Section 5.5 below), but not later than seventy (70) days following the Separation Date; provided however that if the 70th day following the Separation Date occurs in the year following the year in which the Separation Date occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided

5

 


 

further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments missed between the Separation Date and the Release Effective Date;
5.2.2
an amount equal to one (1.0) times the Target Annual Bonus, payable in lump sum no later than seventy (70) days following the Separation Date;
5.2.3
If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the end of the Severance Period; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.3 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.2.4
Executive’s unvested time-based equity grants shall vest as of the Separation Date with respect to that portion of such unvested time-based equity grants that would have vested within the thirteen (13) month period immediately following the Separation Date based solely on the passage of time had Executive remained employed by the Company through such period, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.2.5
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless such options are assumed or substituted in the Change in Control, the date of a Change in Control.
5.3
During the Change in Control Termination Period, by the Company Without Cause or by Executive for Good Reason. If during the Change in Control Termination Period, as defined herein, either the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any payments or benefits under Section 5.2, and subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement, the Company

6

 


 

shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.3.1
The Company shall pay Executive an amount equal to eighteen (18) months of Executive’s then current monthly base salary (less applicable taxes and withholdings) (the “CIC Severance Period”) plus one and a half (1.5) times Executive’s target bonus for the year during which the Separation Date occurs, payable in lump sum no later than seventy (70) days following the Separation Date; provided, that, if the Separation Date occurs within three (3) months prior to a Change in Control, any amounts payable under this Section 5.3.1 (excluding any amount payable under either Section 5.2.1 or 5.2.2 prior to the date thirty (30) days following the date of the Change in Control) shall be paid no later than the date falling on the later of (a) seventy (70) days following the Separation Date, and (b) thirty (30) days following the date of the Change in Control;
5.3.2
If Executive timely and properly elects health continuation coverage under COBRA, during the eighteen (18) month period following the Separation Date, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the eighteen-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.3.3
All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.3.4
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless the applicable options are assumed or substituted in the Change in Control, the date of a Change in Control.

 

5.4
Definition of Change in Control and Change in Control Termination Period.

7

 


 

5.4.1
Change in Control” means and includes each of the following:
(a)
A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, “Subsidiary” means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or
(b)
During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board of Directors (the “Board”) together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)
The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:
(i)
which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
(ii)
after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity;

8

 


 

provided, however, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction, and
(iii)
after which at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity immediately following the date of such transaction were Board members immediately prior to the date of such transaction.
5.4.2
Change in Control Termination Period” shall mean the period beginning three (3) months prior to and ending twelve (12) months following the occurrence of a Change in Control.
5.4.3
Notwithstanding the foregoing, if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”), to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).
5.4.4
The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.
5.5
Required Release. Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide the payments, acceleration, exercise extension and reimbursements under Sections 5.2 and 5.3 is conditioned upon Executive’s execution of a standard form of an enforceable release of claims (the “Release”) and Executive’s compliance with the Restrictive Covenant Agreement. If Executive chooses not to execute such the Release or fails to comply with the Restrictive Covenant Agreement, then the Company’s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time. The Release shall be provided to Executive within ten (10) days of Executive’s separation from service and Executive must execute it within the time period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). Such Release shall not be effective until any applicable revocation period has expired (the “Release Effective Date”).
5.6
Benefits in Lieu of Other Severance. Executive is not entitled to receive any compensation or benefits upon Executive’s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.

9

 


 

6.
Restrictive Covenants. As a condition of continued employment, Executive will continue to be subject to the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, which the Executive previously executed (the “Restrictive Covenant Agreement”). Executive agrees to continue to abide by the terms of the Restrictive Covenant Agreement, or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement, or any subsequent similar agreement, will survive the termination of Executive's employment and/or the termination of this Agreement.
7.
Company Property. Upon the termination of Executive’s employment or upon Company’s earlier request, Executive shall: (i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive’s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive’s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive’s work and transferring that work to other individuals designated by the Company.
8.
EMPLOYEE REPRESENTATION. Executive represents and warrants that Executive’s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.
9.
Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.
10.
ENTIRE AGREEMENT. Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive’s employment with the Company, including the Prior Employment Agreement; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter. Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid. No change

10

 


 

or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.
11.
SEVERABILITY. If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.
12.
Assignment and Successors. The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law.
13.
GOVERNING LAW. This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (“Applicable Federal Law”). Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.
14.
COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.
15.
Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:
15.1
If to the Company, to the Chief Executive Officer of the Company at the Company's headquarters,
15.2
If to Executive, to the last address that the Company has in its personnel records for Executive, or
15.3
At any other address as any Party shall have specified by notice in writing to the other Party.
16.
SECTION 409A OF THE INTERNAL REVENUE CODE. The parties intend that the provisions of this Agreement comply with or are exempt from Section 409A of the Internal

11

 


 

Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.
16.1
Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service.
16.2
Separate Payments. Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.
16.3
Delayed Distribution to Specified Employee. If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company’s sole discretion, that Executive is a Specified Employee of the Company on the date Executive’s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the Separation Date (the “409A Delay Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Specified Employee” shall mean an employee who, on an Identification Date (“Identification Date” shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof. If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.
16.4
Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following: (a) the amount of expenses eligible for reimbursement, or in-kind benefits

12

 


 

provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (c) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.
17.
Parachute Payments. Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "Total Payments"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).
17.1
Order of Reduction. The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code ("Section 409A"), (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.
17.2
Determinations. All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "Independent Advisors"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.

13

 


 

17.3
Additional Reductions. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.
18.
WITHHOLDING. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold.
19.
CLAWBACK. If any law, rule, or regulation applicable to the Company or its Subsidiaries (including any rule or requirement of any nationally recognized stock exchange on which the stock of the Company or its Subsidiaries is listed), or any policy of the Company or its Subsidiaries reasonably designed to comply therewith, requires the forfeiture or recoupment of any amount paid or payable to the Executive hereunder (or under any other agreement between the Executive and the Company or its Subsidiaries or under any plan in which the Executive participates, or otherwise payable to the Executive as compensation for services), the Executive hereby consents to such forfeiture or recoupment, in each case in the time and manner determined by the Company in its reasonable good faith discretion (collectively, the “Clawback”).

 

[The remainder of this page is intentionally left blank.]

 

14

 


 

[Signature Page for Employment Agreement]

 

 

IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.

 

 

DARIO SCIMECA

 

 

 

/s/ DARIO SCIMECA

 

 

 

Precision Biosciences, Inc.

 

/s/ MICHAEL AMOROSO

 

By: Michael Amoroso

 

Title: President and Chief Executive Officer

15

 


EX-10.4 5 dtil-ex10_4.htm EX-10.4 EX-10.4

EXHIBIT 10.4

img75086868_0.jpg 

 

Executive EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and James Jefferson Smith (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

BACKGROUND

The Company wishes to continue to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

1.
EMPLOYMENT. As of the Effective Date, the Company hereby continues to employ Executive as Chief Research Officer of the Company upon the terms and conditions of this Agreement and Executive accepts continued employment with the Company upon the terms and conditions of this Agreement. This Agreement supersedes and replaces Executive’s Employment Agreement with the Company dated November 7, 2022 (the “Prior Employment Agreement”).
2.
NATURE OF EMPLOYMENT/DUTIES. Executive shall serve as Chief Research Officer of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive’s title and position.
2.1
Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.
2.2
Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive’s duties and advance the Company’s interests. During Executive’s employment, Executive may, with the Board’s consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive’s obligations hereunder.

 

 


 

3.
COMPENSATION.
3.1
Base Salary. During the Term, Executive’s annual base salary for all services rendered shall be Four Hundred Thousand and 00/100 Dollars ($400,000.00) (less applicable taxes and withholdings) payable in accordance with the Company’s payroll practices as they may exist from time to time (“Base Salary”). Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company’s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.
3.2
Business Expenses. Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time. All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.
3.3
Bonus. During the Term, Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans. Executive’s annual incentive compensation under such bonus plan (the “Annual Bonus”) shall be targeted at thirty-five percent (35%) of Executive’s Base Salary (such target, as may be increased by the Board from time to time, the “Target Annual Bonus”). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive’s continued employment with the Company through the date of payment.
3.4
Benefits. During the Term, Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive’s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion, as they may exist from time to time. The Company shall pay annual dues and expenses for Executive’s membership and participation in such professional organizations as may be approved by the Board.
3.5
Indemnification; D&O Insurance. Both during and after the Term, the Company hereby agrees to indemnify Executive and hold Executive harmless to the maximum extent permitted by the Company’s organizational documents as in effect from time to time against and in respect of any and all actions, suits, proceedings, investigations, claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages resulting from Executive’s good faith performance of Executive’s duties and obligations with the Company hereunder; provided, that, Executive shall have no rights to indemnification with respect to any amounts subject to Clawback (as defined below). The Company shall cover the Executive under directors’ and officers’ liability insurance to the same extent as the Company covers its other active

2

 


 

officers and directors. The foregoing obligations shall survive the termination of Executive’s employment with the Company.
4.
TERM OF EMPLOYMENT AND TERMINATION. The Company and Executive acknowledge that Executive's employment is and shall continue to be at-will, as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive’s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4. The date on which Executive’s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the “Separation Date.” Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.
4.1
Without Cause, Upon Notice. Either the Company or Executive may terminate Executive’s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.
4.2
For Cause. The Company may terminate Executive’s employment and this Agreement immediately without notice at any time for “Cause,” which shall mean the following:
4.2.1
Executive's material failure to perform Executive’s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors (other than any such failure resulting from incapacity due to physical or mental illness);
4.2.2
Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;
4.2.3
Executive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;
4.2.4
Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;
4.2.5
Executive’s failure to cooperate with the Company in any investigation or formal proceeding;
4.2.6
Executive's material breach of any material obligation under this Agreement, the Restrictive Covenant Agreement (as defined in Section 6), or any other written agreement between the Executive and the Company; or
4.2.7
any material failure by Executive to comply with the Company's written policies or rules, as they may be in effect from time to time.

3

 


 

Provided, however, that prior to termination based on Sections 4.2.1, 4.2.5, 4.2.6 or 4.2.7, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.

4.3
By Death or Disability. Executive’s employment and this Agreement shall terminate upon Executive’s Disability or death. For purposes of this Agreement, “Disability” shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.
4.4
For Good Reason. Executive may terminate Executive’s employment for “Good Reason,” which shall mean the occurrence of any of the following, in each case without the Executive's written consent:
4.4.1
a material reduction in Executive's Base Salary by an amount equivalent to ten percent (10%) or greater, other than a general reduction in Base Salary that affects all similarly situated executives;
4.4.2
material, adverse change in Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law),
4.4.3
an involuntary relocation of the Executive's principal place of employment by more than thirty five (35) miles; or
4.4.4
the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law.

Executive cannot terminate Executive’s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within sixty (60) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to

4

 


 

cure such circumstances. If the Executive does not terminate Executive’s employment for Good Reason within ninety (90) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive’s right to terminate for Good Reason with respect to such grounds.

 

5.
COMPENSATION AND BENEFITS UPON TERMINATION. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "Accrued Obligations"). Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.
5.1
By the Company for Cause or because of Executive’s Death or Disability, or by Executive Without Cause, Upon Notice. If Executive’s employment and this Agreement are terminated by the Company for Cause or because of Executive’s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company’s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.
5.2
By the Company Without Cause or by Executive for Good Reason. If the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.2.1
pay Executive an amount equal to twelve(12) months of Executive’s then current monthly Annual Base Salary (less applicable taxes and withholdings) (the “Severance Amount”), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive’s separation from service and over the twelve month period (the “Severance Period”) commencing on the first such payroll date on or following the Release Effective Date (as defined in Section 5.5 below), but not later than seventy (70) days following the Separation Date; provided however that if the 70th day following the Separation Date occurs in the year following the year in which the Separation Date occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided

5

 


 

further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments missed between the Separation Date and the Release Effective Date;
5.2.2
an amount equal to one (1.0) times the Target Annual Bonus, payable in lump sum no later than seventy (70) days following the Separation Date;
5.2.3
If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the end of the Severance Period; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.3 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.2.4
Executive’s unvested time-based equity grants shall vest as of the Separation Date with respect to that portion of such unvested time-based equity grants that would have vested within the thirteen (13) month period immediately following the Separation Date based solely on the passage of time had Executive remained employed by the Company through such period, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.2.5
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless such options are assumed or substituted in the Change in Control, the date of a Change in Control.
5.3
During the Change in Control Termination Period, by the Company Without Cause or by Executive for Good Reason. If during the Change in Control Termination Period, as defined herein, either the Company terminates Executive’s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive’s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any payments or benefits under Section 5.2, and subject to Executive’s continued compliance with Executive’s obligations under the Restrictive Covenant Agreement, the Company

6

 


 

shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:
5.3.1
The Company shall pay Executive an amount equal to eighteen (18) months of Executive’s then current monthly base salary (less applicable taxes and withholdings) (the “CIC Severance Period”) plus one and a half (1.5) times Executive’s target bonus for the year during which the Separation Date occurs, payable in lump sum no later than seventy (70) days following the Separation Date; provided, that, if the Separation Date occurs within three (3) months prior to a Change in Control, any amounts payable under this Section 5.3.1 (excluding any amount payable under either Section 5.2.1 or 5.2.2 prior to the date thirty (30) days following the date of the Change in Control) shall be paid no later than the date falling on the later of (a) seventy (70) days following the Separation Date, and (b) thirty (30) days following the date of the Change in Control;
5.3.2
If Executive timely and properly elects health continuation coverage under COBRA, during the eighteen (18) month period following the Separation Date, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive and the monthly premium amount paid by Executive immediately prior to the date that Executive’s employment terminated. Such reimbursement shall be paid to the Executive on or before the tenth (10th) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the eighteen-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage;
5.3.3
All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s); and
5.3.4
The right to exercise any outstanding and vested stock options to purchase Company common stock until the earlier of (a) the date one (1) year following the Separation Date, (b) the maximum term of the applicable stock option, and (c) unless the applicable options are assumed or substituted in the Change in Control, the date of a Change in Control.

 

5.4
Definition of Change in Control and Change in Control Termination Period.

7

 


 

5.4.1
Change in Control” means and includes each of the following:
(a)
A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, “Subsidiary” means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or
(b)
During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board of Directors (the “Board”) together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)
The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:
(i)
which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
(ii)
after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity;

8

 


 

provided, however, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction, and
(iii)
after which at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity immediately following the date of such transaction were Board members immediately prior to the date of such transaction.
5.4.2
Change in Control Termination Period” shall mean the period beginning three (3) months prior to and ending twelve (12) months following the occurrence of a Change in Control.
5.4.3
Notwithstanding the foregoing, if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”), to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).
5.4.4
The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.
5.5
Required Release. Notwithstanding any provision of this Agreement to the contrary, the Company’s obligation to provide the payments, acceleration, exercise extension and reimbursements under Sections 5.2 and 5.3 is conditioned upon Executive’s execution of a standard form of an enforceable release of claims (the “Release”) and Executive’s compliance with the Restrictive Covenant Agreement. If Executive chooses not to execute such the Release or fails to comply with the Restrictive Covenant Agreement, then the Company’s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time. The Release shall be provided to Executive within ten (10) days of Executive’s separation from service and Executive must execute it within the time period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). Such Release shall not be effective until any applicable revocation period has expired (the “Release Effective Date”).
5.6
Benefits in Lieu of Other Severance. Executive is not entitled to receive any compensation or benefits upon Executive’s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.

9

 


 

6.
Restrictive Covenants. As a condition of continued employment, Executive will continue to be subject to the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, which the Executive previously executed (the “Restrictive Covenant Agreement”). Executive agrees to continue to abide by the terms of the Restrictive Covenant Agreement, or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement, or any subsequent similar agreement, will survive the termination of Executive's employment and/or the termination of this Agreement.
7.
Company Property. Upon the termination of Executive’s employment or upon Company’s earlier request, Executive shall: (i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive’s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive’s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive’s work and transferring that work to other individuals designated by the Company.
8.
EMPLOYEE REPRESENTATION. Executive represents and warrants that Executive’s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.
9.
Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.
10.
ENTIRE AGREEMENT. Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive’s employment with the Company, including the Prior Employment Agreement; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter. Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid. No change

10

 


 

or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.
11.
SEVERABILITY. If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.
12.
Assignment and Successors. The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law.
13.
GOVERNING LAW. This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (“Applicable Federal Law”). Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.
14.
COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.
15.
Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:
15.1
If to the Company, to the General Counsel of the Company at the Company's headquarters,
15.2
If to Executive, to the last address that the Company has in its personnel records for Executive, or
15.3
At any other address as any Party shall have specified by notice in writing to the other Party.
16.
SECTION 409A OF THE INTERNAL REVENUE CODE. The parties intend that the provisions of this Agreement comply with or are exempt from Section 409A of the Internal

11

 


 

Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.
16.1
Separation from Service. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service.
16.2
Separate Payments. Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.
16.3
Delayed Distribution to Specified Employee. If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company’s sole discretion, that Executive is a Specified Employee of the Company on the date Executive’s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the Separation Date (the “409A Delay Period”). In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period. For purposes of this Agreement, “Specified Employee” shall mean an employee who, on an Identification Date (“Identification Date” shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof. If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.
16.4
Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following: (a) the amount of expenses eligible for reimbursement, or in-kind benefits

12

 


 

provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (c) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.
17.
Parachute Payments. Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "Total Payments"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).
17.1
Order of Reduction. The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code ("Section 409A"), (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.
17.2
Determinations. All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "Independent Advisors"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.

13

 


 

17.3
Additional Reductions. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.
18.
WITHHOLDING. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold.
19.
CLAWBACK. If any law, rule, or regulation applicable to the Company or its Subsidiaries (including any rule or requirement of any nationally recognized stock exchange on which the stock of the Company or its Subsidiaries is listed), or any policy of the Company or its Subsidiaries reasonably designed to comply therewith, requires the forfeiture or recoupment of any amount paid or payable to the Executive hereunder (or under any other agreement between the Executive and the Company or its Subsidiaries or under any plan in which the Executive participates, or otherwise payable to the Executive as compensation for services), the Executive hereby consents to such forfeiture or recoupment, in each case in the time and manner determined by the Company in its reasonable good faith discretion (collectively, the “Clawback”).

 

[The remainder of this page is intentionally left blank.]

 

14

 


 

[Signature Page for Employment Agreement]

 

 

IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.

 

 

JAMES JEFFERSON SMITH

 

 

 

/s/ JAMES JEFFERSON SMITH

 

 

 

Precision Biosciences, Inc.

 

/s/ MICHAEL AMOROSO

 

By: Michael Amoroso

 

Title: President and Chief Executive Officer

 

15

 


GRAPHIC 6 img72316305_0.jpg GRAPHIC begin 644 img72316305_0.jpg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end GRAPHIC 7 img73239826_0.jpg GRAPHIC begin 644 img73239826_0.jpg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end GRAPHIC 8 img74163347_0.jpg GRAPHIC begin 644 img74163347_0.jpg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end GRAPHIC 9 img75086868_0.jpg GRAPHIC begin 644 img75086868_0.jpg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end EX-101.SCH 10 dtil-20240122.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key CIK Entity Tax Identification Number Entity Registrant Name Registrant Name Entity Ex Transition Period Document Period End Date Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Entity Emerging Growth Company Amendment Flag Amendment Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type Document Type XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 22, 2024
Entity Registrant Name Precision BioSciences, Inc.
Entity Central Index Key 0001357874
Entity Emerging Growth Company true
Securities Act File Number 001-38841
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-4206017
Entity Address, Address Line One 302 East Pettigrew St.
Entity Address, Address Line Two Suite A-100
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27701
City Area Code 919
Local Phone Number 314-5512
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.000005 per share
Trading Symbol DTIL
Security Exchange Name NASDAQ
XML 12 dtil-20240122_htm.xml IDEA: XBRL DOCUMENT 0001357874 2024-01-22 2024-01-22 false 0001357874 NASDAQ 8-K 2024-01-22 Precision BioSciences, Inc. DE 001-38841 20-4206017 302 East Pettigrew St. Suite A-100 Durham NC 27701 919 314-5512 false false false false Common Stock, par value $0.000005 per share DTIL true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports dtil-20240122.htm dtil-20240122.xsd http://xbrl.sec.gov/dei/2023 false false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dtil-20240122.htm": { "nsprefix": "dtil", "nsuri": "http://precisionbiosciences.com/20240122", "dts": { "inline": { "local": [ "dtil-20240122.htm" ] }, "schema": { "local": [ "dtil-20240122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7590f60f-7612-4f27-a33f-33c5ca78ab06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240122.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7590f60f-7612-4f27-a33f-33c5ca78ab06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240122.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://precisionbiosciences.com/20240122/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 20 0000950170-24-006661-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-006661-xbrl.zip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end